Premium
Association between plasma interleukin‐17 levels and risk of psoriasis: a meta‐analysis
Author(s) -
Zhou X. Y.,
Bao J.,
Huang B.,
Jin Y.
Publication year - 2017
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.13033
Subject(s) - psoriasis , meta analysis , medicine , association (psychology) , interleukin , immunology , interleukin 17 , cytokine , psychology , psychotherapist
Summary Background Emerging evidence indicates that plasma interleukin ( IL )‐17 levels may be associated with increased risk of psoriasis, but the individual published results are inconclusive. Aim To evaluate IL ‐17 levels in patients with psoriasis using a meta‐analysis of studies comparing IL ‐17 levels in controls and in patients with psoriasis. Methods All relevant studies were identified by searching PubMed, Web of Science and MEDLINE databases before 1 November 2015. Pooled risk estimates were calculated by random‐effects models. Crude OR and standardized mean difference ( SMD ) with corresponding 95% CI were also calculated. Results In total, eight cross‐sectional study studies were included in the final analysis. The mean plasma levels of IL ‐17 were higher in patients with psoriasis than in healthy controls ( SMD = 0.47, 95% CI = 0.07–0.86, P < 0.001). Conclusions Based on this literature review, there appears to be a positive association between IL ‐17 plasma levels and psoriasis.